Symposium 8: Advances in Genomics and Pathology II
Tracks
Parallel Session 3
Wednesday, June 19, 2024 |
10:30 - 11:40 |
Lecture Theatre 3 |
Speaker
Professor Jana Klanova
Professor
Masaryk University
The exposome as a key resource for understanding human disease
10:30 - 11:00
Prof. Gerrit Meijer
Professor of Oncologic Pathology
Netherlands Cancer Institute
Integrating advanced research data across national boundaries for cancer research
11:00 - 11:30Abstract
The mission of pathology is to generate from tissue, cell and DNA samples as much information as possible that is relevant for the best treatment of patients, now and in the future. The latter evidently refers to pathology research.
For generating information, data are crucial. Evidently, this involves data derived from tissue, cell and DNA samples, which are accumulated in massive amounts in modern pathology, Yet, these pathology data alone do not yield information that is relevant for the best treatment of patients. To meet this criterion, additional conditions should be fulfilled. These include that data should be of high quality, data should be structured and standardised, data should be available in sufficiently large numbers to conduct practice changing studies. Moreover, the data required for this purpose are not only restricted tot diagnostics / pathology data, but also to data concerning the interventions that follow the diagnosis, and subsequently the clinical outcome that follows. However, advancing medicine, particularly in pathology, is hindered by the limited availability of comprehensive data resources that meet these criteria. This scarcity is due to complex, multifaceted challenges. Promising developments aimed at overcoming these obstacles and the opportunities they present will be discussed.
For generating information, data are crucial. Evidently, this involves data derived from tissue, cell and DNA samples, which are accumulated in massive amounts in modern pathology, Yet, these pathology data alone do not yield information that is relevant for the best treatment of patients. To meet this criterion, additional conditions should be fulfilled. These include that data should be of high quality, data should be structured and standardised, data should be available in sufficiently large numbers to conduct practice changing studies. Moreover, the data required for this purpose are not only restricted tot diagnostics / pathology data, but also to data concerning the interventions that follow the diagnosis, and subsequently the clinical outcome that follows. However, advancing medicine, particularly in pathology, is hindered by the limited availability of comprehensive data resources that meet these criteria. This scarcity is due to complex, multifaceted challenges. Promising developments aimed at overcoming these obstacles and the opportunities they present will be discussed.
Sara van den Boomen
Senior Sales Specialist - Digital Pathology
Leica Biosystems
Presentation from Gold Sponsor, Leica Biosystems
11:30 - 11:40Chair
Susanne Lens
Professor of Genomic Instability
University Medical Center Utrecht
Gerrit Meijer
Professor of Oncologic Pathology
Netherlands Cancer Institute